US20230212143A9 - Prmt5 inhibitor compounds - Google Patents
Prmt5 inhibitor compounds Download PDFInfo
- Publication number
- US20230212143A9 US20230212143A9 US17/599,505 US202017599505A US2023212143A9 US 20230212143 A9 US20230212143 A9 US 20230212143A9 US 202017599505 A US202017599505 A US 202017599505A US 2023212143 A9 US2023212143 A9 US 2023212143A9
- Authority
- US
- United States
- Prior art keywords
- optionally substituted
- compound
- pharmaceutically acceptable
- prodrug
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 230
- 229940125897 PRMT5 inhibitor Drugs 0.000 title abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 84
- 201000010099 disease Diseases 0.000 claims abstract description 54
- 150000003839 salts Chemical class 0.000 claims description 104
- 239000000651 prodrug Substances 0.000 claims description 91
- 229940002612 prodrug Drugs 0.000 claims description 91
- 239000012453 solvate Substances 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 66
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 230000002062 proliferating effect Effects 0.000 claims description 31
- -1 substituted Chemical class 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 23
- 125000001931 aliphatic group Chemical group 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 12
- 125000003107 substituted aryl group Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 125000002619 bicyclic group Chemical group 0.000 claims description 9
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000002950 monocyclic group Chemical group 0.000 claims description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910004749 OS(O)2 Inorganic materials 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Chemical group 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 3
- 239000011593 sulfur Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 abstract description 30
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 abstract description 26
- 238000011282 treatment Methods 0.000 abstract description 23
- 208000024891 symptom Diseases 0.000 abstract description 9
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000027455 binding Effects 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- 101000924530 Homo sapiens Protein arginine N-methyltransferase 5 Proteins 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 23
- 239000003112 inhibitor Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 17
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 16
- 229960001570 ademetionine Drugs 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 13
- 206010039491 Sarcoma Diseases 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 206010025323 Lymphomas Diseases 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000002255 enzymatic effect Effects 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 101000582546 Homo sapiens Methylosome protein 50 Proteins 0.000 description 8
- 102100030528 Methylosome protein 50 Human genes 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 125000001475 halogen functional group Chemical group 0.000 description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 7
- 101100434927 Caenorhabditis elegans prmt-5 gene Proteins 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010005949 Bone cancer Diseases 0.000 description 6
- 208000018084 Bone neoplasm Diseases 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 6
- 206010024612 Lipoma Diseases 0.000 description 6
- 208000034578 Multiple myelomas Diseases 0.000 description 6
- 206010029260 Neuroblastoma Diseases 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000037393 large granular lymphocyte leukemia Diseases 0.000 description 6
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 201000008968 osteosarcoma Diseases 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 125000005907 alkyl ester group Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 230000006217 arginine-methylation Effects 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100026024 Acyl-coenzyme A synthetase ACSM3, mitochondrial Human genes 0.000 description 3
- 238000012815 AlphaLISA Methods 0.000 description 3
- 201000003076 Angiosarcoma Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 3
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 201000005262 Chondroma Diseases 0.000 description 3
- 208000005243 Chondrosarcoma Diseases 0.000 description 3
- 201000009047 Chordoma Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
- 208000007569 Giant Cell Tumors Diseases 0.000 description 3
- 208000002927 Hamartoma Diseases 0.000 description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 description 3
- 206010019629 Hepatic adenoma Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 208000002260 Keloid Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 3
- 206010027406 Mesothelioma Diseases 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 description 3
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000005678 Rhabdomyoma Diseases 0.000 description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 3
- 201000002143 bronchus adenoma Diseases 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 201000005217 chondroblastoma Diseases 0.000 description 3
- 201000010897 colon adenocarcinoma Diseases 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 238000007824 enzymatic assay Methods 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000010749 gastric carcinoma Diseases 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000024348 heart neoplasm Diseases 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000006359 hepatoblastoma Diseases 0.000 description 3
- 201000002735 hepatocellular adenoma Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000001117 keloid Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 201000004593 malignant giant cell tumor Diseases 0.000 description 3
- 210000002418 meninge Anatomy 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 208000009091 myxoma Diseases 0.000 description 3
- ZKXZLIFRWWKZRY-KRWDZBQOSA-N n-[(2s)-3-(3,4-dihydro-1h-isoquinolin-2-yl)-2-hydroxypropyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide Chemical compound C([C@H](O)CN1CC2=CC=CC=C2CC1)NC(=O)C(N=CN=1)=CC=1NC1COC1 ZKXZLIFRWWKZRY-KRWDZBQOSA-N 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 208000003388 osteoid osteoma Diseases 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000037426 transcriptional repression Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 210000003905 vulva Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical class N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100034523 Histone H4 Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 102100027120 Low-density lipoprotein receptor-related protein 12 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101710098570 Suppressor of tumorigenicity 7 protein Proteins 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008275 binding mechanism Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 description 2
- 125000004995 haloalkylthio group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000005358 mercaptoalkyl group Chemical group 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000004963 sulfonylalkyl group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WWOOWAHTEXIWBO-QFRSUPTLSA-N (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(R)-hydroxy(phenyl)methyl]oxolane-3,4-diol Chemical compound NC=1C2=C(N=CN=1)N(C=C2)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)[C@@H](C1=CC=CC=C1)O WWOOWAHTEXIWBO-QFRSUPTLSA-N 0.000 description 1
- JPFGFRMPGVDDGE-GWRCVIBKSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-2,3,4-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O)[C@@](O)(CO)OC1 JPFGFRMPGVDDGE-GWRCVIBKSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- SYYSBZOSEAUMEY-UHFFFAOYSA-N 1,1,1-trifluoro-2-$l^{1}-sulfanylethane Chemical group FC(F)(F)C[S] SYYSBZOSEAUMEY-UHFFFAOYSA-N 0.000 description 1
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical group C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- YPJMOVVQKBFRNH-UHFFFAOYSA-N 1-(9-ethylcarbazol-3-yl)-n-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1CNCC1=CC=CC=N1 YPJMOVVQKBFRNH-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000007426 Cellular thermal shift assay Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 description 1
- 101710136206 S-methyl-5'-thioadenosine phosphorylase Proteins 0.000 description 1
- 101000985737 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Protein arginine N-methyltransferase HSL7 Proteins 0.000 description 1
- 101000651946 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein arginine N-methyltransferase skb1 Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- VVGPECAOVDZTLZ-UHFFFAOYSA-N [N]NC(N)=N Chemical group [N]NC(N)=N VVGPECAOVDZTLZ-UHFFFAOYSA-N 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 description 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 description 1
- 125000006809 haloalkylaminocarbonyl group Chemical group 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000051124 human PRMT5 Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- DBSMLQTUDJVICQ-CJODITQLSA-N onametostat Chemical compound NC1=C2C=CN([C@@H]3C[C@H](CCC4=CC=C5C=C(Br)C(N)=NC5=C4)[C@@H](O)[C@H]3O)C2=NC=N1 DBSMLQTUDJVICQ-CJODITQLSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- VEMKTZHHVJILDY-UHFFFAOYSA-N resmethrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UHFFFAOYSA-N 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001395 thiirenyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- PRMT5 Protein arginine methyltransferase 5
- SAM S-adenosylmethionine
- Arginine methylation of proteins plays a crucial function in a variety of cellular pathways including cell growth and proliferation, apoptosis, angiogenesis, and metastasis by regulating both transcriptional and post-transcriptional RNA processing.
- This modification is catalyzed by the protein arginine methyltransferase (PRMT), which transfers a methyl group from S-adenosylmethionine (SAM) to the terminal guanidino nitrogen atoms of arginine side-chains of histone and nonhistone proteins.
- PRMT protein arginine methyltransferase
- SAM S-adenosylmethionine
- PRMT5 is the major type II PRMT which catalyzes the formation of ⁇ -NG-monomethyl and ⁇ -NG,N′G-symmetric dimethyl arginine residues.
- PRMT5 has been shown to be involved in transcriptional repression including that of tumor suppressor and cell cycle genes like ST7 (suppressor of tumorigenicity 7 protein), 2 cyclin E1 and CDKN2A (cyclin-dependent kinase inhibitor 2A).
- PRMT5 has attracted increasing attention as an anticancer target. It is overexpressed in various cancers, including lymphoma, prostate cancer, glioblastoma, and colorectal carcinoma and is associated with poor prognosis.
- PRMT5 inhibitors there are two types according to their binding sites.
- co-factor site such as LLY-283
- This invention is directed towards compounds, compositions, and methods of treating disease, disorders and conditions in a subject, including, inflammation, cancer, and autoimmune diseases by use of the compounds and compositions thereof.
- the invention is directed to a compound of Formula (I) or (II), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
- each R 2 is independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted —C(O)—NH-aryl, or optionally substituted —C(O)-heterocycloalkyl.
- the invention is directed to a compound of Formula (I) or (II), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
- each L is independently
- each R 2 is independently
- the compound of Formula (I) or (II), is any of
- the invention is directed to a compound of Formula (III), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
- Ar 1 is a monocyclic or bicyclic aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ar 1 is substituted with 0, 1, 2, 3, 4, or 5 R y groups, as valency permits; each R y is independently selected from the group consisting of halo, —CN, —NO 2 , optionally substituted aliphatic, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —OR A , —N(R B ) 2 , —SR A , —C( ⁇ O)R A , —C(O)OR A , —C(O)SR A , —C(O)N(R B ) 2 , —C(O)N(R B )N(R B ) 2 , —OC(O)R A , —OC(O)N(R B ) 2 , —NR B C(O)R A
- each R A is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
- each R B is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R B groups are taken together with their intervening atoms to for an optionally substituted heterocyclic ring, which may be optionally substituted with 0, 1, 2, 3, 4, or 5 R x groups;
- each R A and R B can be optionally substituted by one or more independent R 5 , R 6 , R 7 , and R 8 ;
- each R 5 , R 6 , R 7 , and R 8 is independently hydrogen, halo, or optionally substituted aliphatic;
- each R x is independently selected from the group consisting of halo, —CN, optionally substituted aliphatic, —OR′, and —N(R′′) 2 ;
- each R′ is independently hydrogen or optionally substituted aliphatic
- each R′′ is independently hydrogen or optionally substituted aliphatic, or two R′′ are taken together with their intervening atoms to form a heterocyclic ring: and n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, as valency permits;
- Ar 2 is any one of the following groups:
- the compounds of Formula III are those wherein:
- Ar 1 is any one of the following groups,
- the compounds of Formula III or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, is one of the following:
- the invention provides compounds, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, represented by Formula (IV) or (V):
- each R 1 is independently one of:
- Each L is independently:
- Each R 2 is independently one of:
- the compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof is any of:
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and a pharmaceutically acceptable carrier.
- the pharmaceutical composition further comprises an additional therapeutic agent (e.g., an anticancer agent).
- the invention provides a method of treating a disease, disorder, or symptom thereof in a subject, comprising administering to the subject any compound or composition delineated herein.
- the compound or composition is administered in an amount and under conditions sufficient to ameliorate the disease, disorder, or symptom thereof in a subject.
- the invention provides a method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said proliferative disease.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said proliferative disease.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of modulating the proliferation activity in a subject, comprising contacting the subject with a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in an amount and under conditions sufficient to modulate proliferation activity.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a subject suffering from or susceptible to a proliferation related disorder or disease, comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a subject suffering from or susceptible to a proliferation related activity related disorder or disease, wherein the subject has been identified as in need of treatment for a proliferation related disorder or disease, comprising administering to said subject in need thereof, a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said disorder.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formula
- the invention provides a method of treating a subject suffering from or susceptible to a cell proliferation related disorder or disease, wherein the subject has been identified as in need of treatment for a cell proliferation related disorder or disease, comprising administering to said subject in need thereof, a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that cell proliferation in said subject is modulated (e.g., down regulated).
- the compounds or compositions delineated herein preferentially target cancer cells over nontransformed cells.
- the proliferative disease is cancer.
- the cancer is multiple myeloma, lymphoma, chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), large granular lymphocyte leukemia (LGL), sarcoma, lung cancer, breast cancer, renal cancer, prostate cancer, pancreatic cancer, melanoma, colon carcinoma, gastric carcinoma, cervical cancer, ovarian cancer, liver cancer, or head and neck cancer.
- CLL chronic lymphocytic leukemia
- AML acute myelogenous leukemia
- LGL large granular lymphocyte leukemia
- sarcoma lung cancer, breast cancer, renal cancer, prostate cancer, pancreatic cancer, melanoma, colon carcinoma, gastric carcinoma, cervical cancer, ovarian cancer, liver cancer, or head and neck cancer.
- the invention provides a method of treating cancer, tumor growth, cancer of the colon, breast, bone, brain and others (e.g., osteosarcoma, neuroblastoma, colon adenocarcinoma), comprising administering to said subject in need thereof, an effective amount of any compound delineated herein, or a pharmaceutically acceptable salt thereof.
- a method of treating cancer, tumor growth, cancer of the colon, breast, bone, brain and others comprising administering to said subject in need thereof, an effective amount of any compound delineated herein, or a pharmaceutically acceptable salt thereof.
- cardiac cancer e.g., sarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma
- lung cancer e.g., bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma
- various gastrointestinal cancer e.g., cancers of esophagus, stomach, pancreas, small bowel, and large bowel
- genitourinary tract cancer e.g., kidney, bladder and urethra, prostate, testis
- liver cancer e.g., hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma
- bone cancer e.g., osteogenic s
- the disorder of uncontrolled cellular proliferation is cancer.
- the cancer is selected from prostate cancer, lung cancer, colon cancer, pancreatic cancer, head & neck cancer, skin cancer, brain cancer, breast cancer, testicular cancer, and ovarian cancer.
- the cancer is selected from melanoma, glioma, lymphoma, and leukemia.
- Methods delineated herein include those wherein the subject is identified as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
- FIG. 1 depicts (A) Arginine methylation reaction catalyzed by three types of PRMTs. (B) Chemical structures of SAM and SAH. 13
- FIG. 2 depicts schematic representation of the AlphaLISA detection of a methylated histone peptide.
- B biotin group
- R arginine residue
- Me methyl group
- FIG. 3 depicts AlphaLISA assay protocol.
- FIG. 4 depicts lead optimization of compounds of the invention based on enzymatic assay.
- FIG. 5 depicts the proposed binding poses of CMP 5 bound to PRMT 5.
- FIG. 6 depicts the proposed binding poses of 1-ET-1F bound to PRMT 5.
- FIG. 7 depicts the overall structure of PRMT5:MEP50 complex (PDB code 4GQB).
- FIG. 8 depicts SPR binding results of CMP5 and 6-1F.
- FIG. 9 depicts MCF-7 cell viability of PRMT 5 inhibitors
- FIGS. 10 A- 10 B depict MCF-7 and MCF-10A cell viability of 4-ET-3F ( FIG. 10 A ) and 8-ET-4F ( FIG. 10 B ).
- FIG. 11 depicts Scheme 1—synthetic route of 1-ET-1F15.
- FIG. 12 depicts types of arginine methylation.
- FIG. 13 depicts the crystal structure of human PRMT5:MEP50 (PDB 4GQB).
- the first class is cofactor-competitive inhibitors, which are always cofactor analogs contain a nucleoside moiety whose ribose and adenine sub-structures are strongly favored by the Rossmann fold motif which recognizes nucleoside-based cofactors specifically.
- the second class is H4 substrate-competitive inhibitors.
- FIG. 15 depicts chemical structures of PRMT5 inhibitors.
- FIG. 16 depicts SPR binding experiments for binding affinity (K D ) determination and competitive binding analysis for compounds.
- FIG. 17 depicts (A-B) Mechanism of inhibition (MOI) study of 1-ET-1F by enzymatic assay suggested that it might be a substrate-competitive inhibitor. (C-D) predicted binding modes of 1-ET-1F at the substrate binding pocket in the presence of MTA.
- MOI Mechanism of inhibition
- FIG. 18 depicts (A) Anti-proliferative effect of designed molecules in different cancel cell lines (48h). (B) Western blot result showed a decreased protein symmetric demethylation level in MV4-11 cell line (48h).
- FIG. 19 depicts apoptotic effects of 1-ET-1F in a dose-dependent manner in MV4-11 cell line.
- FIG. 20 depicts enzymatic inhibition assay results for 11-series compounds.
- FIG. 21 depicts enzymatic inhibition assay results for 15-series compounds.
- FIG. 22 depicts representative compound 11-9F binding to PRMT5 results using SPR/Biacore.
- Upper panel shows the compound binding to apo PRMT5/MEP50 complex with Kd of 4.3 uM; lower panel shows the compound binding to PRMT5/MTA/MEP50 holo complex with Kd of 162 nM.
- FIG. 23 shows that test compounds bind to PRMT5/MEP50 complex with or without MTA/SAM/SAH binding to the cofactor site, uniquely targeting MTAP deletion subset of cancers.
- FIG. 23 depicts enzymatic inhibition assay results and binding affinity results for test compounds.
- FIG. 24 depicts representative compound 11-9F cellular target engagement results using a Cellular Thermal Shift Assay.
- Left panel demonstrates that compared to negative control compound 11-3F, 11-9F binds to PRMT5 in the MDA-MB-231 triple negative breast cancer cells, resulting in increased thermal stability; right panel quantifies the PRMT5 melting temperature increase of 1.5 degree Celsius due to 11-9F binding.
- FIG. 25 depicts effects of compound 11-9F in cells, MDA-MB-231 breast cancer cell line.
- treating encompasses ameliorating, mitigating and/or managing the disorder and/or conditions that may cause the disorder.
- the terms “treating” and “treatment” refer to a method of alleviating or abating a disease and/or its attendant symptoms.
- “treating” includes blocking, inhibiting, attenuating, modulating, reversing the effects of and reducing the occurrence of e.g., the harmful effects of a disorder.
- inhibiting encompasses preventing, reducing and halting progression.
- activating encompasses permitting, increasing and enhancing progression.
- modulate refers to increases or decreases in the activity of a cell in response to exposure to a compound of the invention.
- isolated refers to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. Particularly, in embodiments the compound is at least 85% pure, more preferably at least 90% pure, more preferably at least 95% pure, and most preferably at least 99% pure.
- polypeptide “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues.
- the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.
- a “peptide” is a sequence of at least two amino acids. Peptides can consist of short as well as long amino acid sequences, including proteins.
- amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
- Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ -carboxyglutamate, and O-phosphoserine.
- Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
- Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
- protein refers to series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.
- Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
- amino acid sequences As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.
- Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3rd ed., 1994) and Cantor and Schimmel, Biophysical Chemistry Part I. The Conformation of Biological Macromolecules (1980).
- Primary structure refers to the amino acid sequence of a particular peptide.
- Secondary structure refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 50 to 350 amino acids long.
- Typical domains are made up of sections of lesser organization such as stretches of ⁇ -sheet and ⁇ -helices.
- Tetiary structure refers to the complete three dimensional structure of a polypeptide monomer.
- Quaternary structure refers to the three dimensional structure formed by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.
- administration includes routes of introducing the compound(s) to a subject to perform their intended function.
- routes of administration include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), topical, oral, inhalation, rectal and transdermal.
- an effective amount includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result.
- An effective amount of compound may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response.
- An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the elastase inhibitor compound are outweighed by the therapeutically beneficial effects.
- systemic administration means the administration of a compound(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes.
- terapéuticaally effective amount refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.
- a therapeutically effective amount of compound may range from about 0.005 ⁇ g/kg to about 200 mg/kg, preferably about 0.01 mg/kg to about 200 mg/kg, more preferably about 0.015 mg/kg to about 30 mg/kg of body weight. In other embodiments, the therapeutically effect amount may range from about 1.0 pM to about 10 ⁇ M.
- treatment of a subject with a therapeutically effective amount of a compound can include a single treatment or, preferably, can include a series of treatments.
- a subject is treated with a compound in the range of between about 0.005 ⁇ g/kg to about 200 mg/kg of body weight, one time per day for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks.
- a subject may be treated daily for several years in the setting of a chronic condition or illness. It will also be appreciated that the effective dosage of a compound used for treatment may increase or decrease over the course of a particular treatment.
- chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
- diastereomers refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.
- enantiomers refers to two stereoisomers of a compound which are non-superimposable mirror images of one another.
- An equimolar mixture of two enantiomers is called a “racemic mixture” or a “racemate.”
- isomers or “stereoisomers” refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
- prodrug includes compounds with moieties which can be metabolized in vivo. Generally, the prodrugs are metabolized in vivo by esterases or by other mechanisms to active drugs. Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19).
- the prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid.
- prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides.
- prodrug moieties are propionoic acid esters and acyl esters.
- Prodrugs which are converted to active forms through other mechanisms in vivo are also included.
- the compounds of the invention are prodrugs of any of the formulae herein.
- subject refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In certain embodiments, the subject is a human.
- the term “about,” when referring to a value is meant to encompass variations of, in some embodiments ⁇ 20%, in some embodiments ⁇ 10%, in some embodiments ⁇ 5%, in some embodiments ⁇ 1%, in some embodiments ⁇ 0.5%, and in some embodiments ⁇ 0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.
- the compounds of the invention include olefins having either geometry: “Z” refers to what is referred to as a “cis” (same side) conformation whereas “E” refers to what is referred to as a “trans” (opposite side) conformation.
- Z refers to what is referred to as a “cis” (same side) conformation
- E refers to what is referred to as a “trans” (opposite side) conformation.
- d and “1” configuration are as defined by the IUPAC Recommendations.
- diastereomer, racemate, epimer and enantiomer these will be used in their normal context to describe the stereochemistry of preparations.
- alkyl refers to a straight-chained or branched hydrocarbon group containing 1 to 12 carbon atoms.
- the term “lower alkyl” refers to a C1-C6 alkyl chain. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, tert-butyl, and n-pentyl. Alkyl groups may be optionally substituted with one or more substituents.
- haloalkyl refers to an alkyl group that is substituted by one or more halo substituents.
- haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, bromomethyl, chloromethyl, and 2,2,2-trifluoroethyl.
- alkenyl refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon double bond. Alkenyl groups may be optionally substituted with one or more substituents.
- alkynyl refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing the 2 to 12 carbon atoms and at least one carbon-carbon triple bond. Alkynyl groups may be optionally substituted with one or more substituents.
- arylalkynyl refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon triple bond wherein one or more of the sp hybridized carbons of the alkynyl unit attaches to an aryl moiety.
- Alkynyl groups may be optionally substituted with one or more substituents.
- the sp 2 or sp carbons of an alkenyl group and an alkynyl group, respectively, may optionally be the point of attachment of the alkenyl or alkynyl groups.
- alkoxy refers to an —O-alkyl radical.
- halogen means —F, —Cl, —Br or —I.
- alkylthio refers to an —S-alkyl substituent.
- alkoxyalkyl refers to an -alkyl-O-alkyl substituent.
- haloalkoxy refers to an —O-alkyl that is substituted by one or more halo substituents.
- haloalkoxy groups include trifluoromethoxy, and 2,2,2-trifluoroethoxy.
- haloalkoxyalkyl refers to an -alkyl-O-alkyl′ where the alkyl′ is substituted by one or more halo substituents.
- haloalkylaminocarbonyl refers to a —C(O)-amino-alkyl where the alkyl is substituted by one or more halo substituents.
- haloalkylthio refers to an —S-alkyl that is substituted by one or more halo substituents.
- haloalkylthio groups include trifluoromethylthio, and 2,2,2-trifluoroethylthio.
- haloalkylcarbonyl refers to an —C(O)-alkyl that is substituted by one or more halo substituents.
- An example of a haloalkylcarbonyl group includes trifluoroacetyl.
- cycloalkyl refers to a hydrocarbon 3-8 membered monocyclic or 7-14 membered bicyclic ring system having at least one saturated ring or having at least one non-aromatic ring, wherein the non-aromatic ring may have some degree of unsaturation.
- Cycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a cycloalkyl group may be substituted by a substituent.
- Representative examples of cycloalkyl group include cyclopropyl, cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
- cycloalkoxy refers to an —O-cycloalkyl substituent.
- cycloalkoxyalkyl refers to an -alkyl-O-cycloalkyl substituent.
- cycloalkylalkoxy refers to an —O-alkyl-cycloalkyl substituent.
- cycloalkylaminocarbonyl refers to an —C(O)—NH-cycloalkyl substituent.
- aryl refers to a hydrocarbon monocyclic, bicyclic or tricyclic aromatic ring system.
- Aryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, 4, 5 or 6 atoms of each ring of an aryl group may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like.
- aryloxy refers to an —O-aryl substituent.
- arylalkoxy refers to an —O-alkyl-aryl substituent.
- arylalkylthio refers to an —S-alkyl-aryl substituent.
- arylthioalkyl refers to an -alkyl-S-aryl substituent.
- arylalkylaminocarbonyl refers to a —C(O)-amino-alkyl-aryl substituent.
- arylalkylsulfonyl refers to an —S(O) 2 -alkyl-aryl substituent.
- arylalkylsulfinyl refers to an —S(O)-alkyl-aryl substituent.
- aryloxyalkyl refers to an -alkyl-O-aryl substituent.
- alkylaryl refers to an -aryl-alkyl substituent.
- arylalkyl refers to an -alkyl-aryl substituent.
- heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-4 ring heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and the remainder ring atoms being carbon (with appropriate hydrogen atoms unless otherwise indicated).
- Heteroaryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may be substituted by a substituent.
- heteroaryl groups include pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoquinolinyl, indazolyl, and the like.
- heteroaryloxy refers to an —O-heteroaryl substituent.
- heteroarylalkoxy refers to an —O-alkyl-heteroaryl substituent.
- heteroaryloxyalkyl refers to an -alkyl-O-heteroaryl substituent.
- nitrogen-containing heteroaryl refers to a heteroaryl group having 1-4 ring nitrogen heteroatoms if monocyclic, 1-6 ring nitrogen heteroatoms if bicyclic, or 1-9 ring nitrogen heteroatoms if tricyclic.
- heterocycloalkyl refers to a nonaromatic 3-8 membered monocyclic, 7-12 membered bicyclic, or 10-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, S, B, P or Si, wherein the nonaromatic ring system is completely saturated.
- Heterocycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heterocycloalkyl group may be substituted by a substituent.
- heterocycloalkyl groups include piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,3-dioxolane, tetrahydrofuranyl, tetrahydrothienyl, thiirenyl, and the like.
- alkylamino refers to an amino substituent which is further substituted with one or two alkyl groups.
- aminoalkyl refers to an alkyl substituent which is further substituted with one or more amino groups.
- hydroxyalkyl or hydroxylalkyl refers to an alkyl substituent which is further substituted with one or more hydroxyl groups.
- alkyl or aryl portion of alkylamino, aminoalkyl, mercaptoalkyl, hydroxyalkyl, mercaptoalkoxy, sulfonylalkyl, sulfonylaryl, alkylcarbonyl, and alkylcarbonylalkyl may be optionally substituted with one or more substituents.
- Acids and bases useful in the methods herein are known in the art.
- Acid catalysts are any acidic chemical, which can be inorganic (e.g., hydrochloric, sulfuric, nitric acids, aluminum trichloride) or organic (e.g., camphorsulfonic acid, p-toluenesulfonic acid, acetic acid, ytterbium triflate) in nature. Acids are useful in either catalytic or stoichiometric amounts to facilitate chemical reactions.
- Bases are any basic chemical, which can be inorganic (e.g., sodium bicarbonate, potassium hydroxide) or organic (e.g., triethylamine, pyridine) in nature. Bases are useful in either catalytic or stoichiometric amounts to facilitate chemical reactions.
- Alkylating agents are any reagent that is capable of effecting the alkylation of the functional group at issue (e.g., oxygen atom of an alcohol, nitrogen atom of an amino group).
- Alkylating agents are known in the art, including in the references cited herein, and include alkyl halides (e.g., methyl iodide, benzyl bromide or chloride), alkyl sulfates (e.g., methyl sulfate), or other alkyl group-leaving group combinations known in the art.
- Leaving groups are any stable species that can detach from a molecule during a reaction (e.g., elimination reaction, substitution reaction) and are known in the art, including in the references cited herein, and include halides (e.g., I—, Cl—, Br—, F—), hydroxy, alkoxy (e.g., —OMe, —O-t-Bu), acyloxy anions (e.g., —OAc, —OC(O)CF 3 ), sulfonates (e.g., mesyl, tosyl), acetamides (e.g., —NHC(O)Me), carbamates (e.g., N(Me)C(O)Ot-Bu), phosphonates (e.g., —OP(O)(OEt) 2 ), water or alcohols (protic conditions), and the like.
- halides e.g., I—, Cl—, Br—, F—
- alkoxy
- substituents on any group can be at any atom of that group, wherein any group that can be substituted (such as, for example, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, heterocycloalkyl) can be optionally substituted with one or more substituents (which may be the same or different), each replacing a hydrogen atom.
- substituents include, but are not limited to alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, halogen, haloalkyl, cyano, nitro, alkoxy, aryloxy, hydroxyl, hydroxylalkyl, oxo (i.e., carbonyl), carboxyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, aryloxycarbonyl, heteroaryloxy, heteroaryloxycarbonyl, thio, mercapto, mercaptoalkyl, arylsulfonyl, amino, aminoalkyl, dialkylamino, alkylcarbonylamino, alkylaminocarbonyl, alkoxycarbonylamino, alkylamino, arylamino, diary
- Additional reaction schemes and protocols may be determined by the skilled artesian by use of commercially available structure-searchable database software, for instance, SciFinder® (CAS division of the American Chemical Society) and CrossFire Beilstein® (Elsevier MDL), or by appropriate keyword searching using an internet search engine such as Google® or keyword databases such as the US Patent and Trademark Office text database.
- SciFinder® CAS division of the American Chemical Society
- CrossFire Beilstein® Elsevier MDL
- the compounds herein may also contain linkages (e.g., carbon-carbon bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring or double bond. Accordingly, all cis/trans and E/Z isomers are expressly included in the present invention.
- the compounds herein may also be represented in multiple tautomeric forms, in such instances, the invention expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented. All such isomeric forms of such compounds herein are expressly included in the present invention. All crystal forms and polymorphs of the compounds described herein are expressly included in the present invention. Also embodied are extracts and fractions comprising compounds of the invention.
- isomers is intended to include diastereoisomers, enantiomers, regioisomers, structural isomers, rotational isomers, tautomers, and the like.
- the methods of the invention may be carried out with an enantiomerically enriched compound, a racemate, or a mixture of diastereomers.
- solvates e.g., hydrates
- solvate refers to the physical association of a compound of the invention with one or more solvent or water molecules, whether organic or inorganic. In certain instances, the solvate is capable of isolation, for example, when one or more solvate molecules are incorporated in the crystal lattice of the crystalline solid.
- Preferred enantiomerically enriched compounds have an enantiomeric excess of 50% or more, more preferably the compound has an enantiomeric excess of 60%, 70%, 80%, 90%, 95%, 98%, or 99% or more.
- only one enantiomer or diastereomer of a chiral compound of the invention is administered to cells or a subject.
- This invention is directed towards compounds, compositions, and methods of treating diseases and disorders by use of the compounds and compositions delineated herein.
- the invention provides a method of treating a disease, disorder, or symptom thereof in a subject, comprising administering to the subject any compound or composition delineated herein.
- the compound or composition is administered in an amount and under conditions sufficient to ameliorate the disease, disorder, or symptom thereof in a subject.
- the disease, disorder, or symptom includes proliferative diseases and disorders, cancer, tumor growth, cancer of the colon, breast, bone, brain and others (e.g., osteosarcoma, neuroblastoma, colon adenocarcinoma), cardiac cancer (e.g., sarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma); lung cancer (e.g., bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma); various gastrointestinal cancer (e.g., cancers of esophagus, stomach, pancreas, small bowel, and large bowel); genitourinary tract cancer (e.g., kidney, bladder and urethra, prostate, testis; liver cancer (e.g., hepatoma, cholangiocarcino
- the inhibition is in vitro. In another aspect, the inhibition is in vivo. In another aspect, the method further comprises administering the compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, to a subject.
- the invention provides a method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said proliferative disease.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said proliferative disease.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of modulating the proliferation activity in a subject, comprising contacting the subject with a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in an amount and under conditions sufficient to modulate proliferation activity.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a subject suffering from or susceptible to a proliferation related disorder or disease, comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formulae (I)-(II), formulae (I)-(V)
- the invention provides a method of treating a subject suffering from or susceptible to a proliferation related activity related disorder or disease, wherein the subject has been identified as in need of treatment for a proliferation related disorder or disease, comprising administering to said subject in need thereof, a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said disorder.
- a compound of any of the formulae herein e.g., formulae (I)-(II), formulae (I)-(V)
- a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof e.g., formula
- the invention provides a method of treating a subject suffering from or susceptible to a cell proliferation related disorder or disease, wherein the subject has been identified as in need of treatment for a cell proliferation related disorder or disease, comprising administering to said subject in need thereof, a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that cell proliferation in said subject is modulated (e.g., down regulated).
- the compounds or compositions delineated herein preferentially target cancer cells over nontransformed cells.
- the proliferative disease is cancer.
- the cancer is multiple myeloma, lymphoma, chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), large granular lymphocyte leukemia (LGL), sarcoma, lung cancer, breast cancer, renal cancer, prostate cancer, pancreatic cancer, melanoma, colon carcinoma, gastric carcinoma, cervical cancer, ovarian cancer, liver cancer, or head and neck cancer.
- CLL chronic lymphocytic leukemia
- AML acute myelogenous leukemia
- LGL large granular lymphocyte leukemia
- sarcoma lung cancer, breast cancer, renal cancer, prostate cancer, pancreatic cancer, melanoma, colon carcinoma, gastric carcinoma, cervical cancer, ovarian cancer, liver cancer, or head and neck cancer.
- the invention provides a method of treating cancer, tumor growth, cancer of the colon, breast, bone, brain and others (e.g., osteosarcoma, neuroblastoma, colon adenocarcinoma), comprising administering to said subject in need thereof, an effective amount of any compound or seaweed extract delineated herein, and pharmaceutically acceptable salts thereof.
- a method of treating cancer, tumor growth, cancer of the colon, breast, bone, brain and others e.g., osteosarcoma, neuroblastoma, colon adenocarcinoma
- cardiac cancer e.g., sarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma
- lung cancer e.g., bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma
- various gastrointestinal cancer e.g., cancers of esophagus, stomach, pancreas, small bowel, and large bowel
- genitourinary tract cancer e.g., kidney, bladder and urethra, prostate, testis
- liver cancer e.g., hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma
- bone cancer e.g., osteogenic s
- Methods delineated herein include those wherein the subject is identified as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition further comprising an additional therapeutic agent. In another embodiment, the invention provides a pharmaceutical composition further comprising an additional therapeutic agent. In a further embodiment, the additional therapeutic agent is an anti-cancer agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, an anti-proliferation agent. In a further embodiment, the additional therapeutic agent is an anti-cancer agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, or an anti-proliferation agent.
- the invention provides a kit comprising an effective amount of a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in unit dosage form, together with instructions for administering the compound to a subject suffering from or susceptible to a proliferative disease, cancer (including diseases herein), solid tumor, angiogenesis, etc.
- a proliferative disease e.g., cancer (including diseases herein), solid tumor, angiogenesis, etc.
- the invention provides a kit comprising an effective amount of a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in unit dosage form, together with instructions for administering the compound to a subject suffering from or susceptible to a cell proliferation disease or disorder, including cancer, solid tumor, angiogenesis, etc.
- a cell proliferation disease or disorder including cancer, solid tumor, angiogenesis, etc.
- pharmaceutically acceptable salts or “pharmaceutically acceptable carrier” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)).
- Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present invention.
- the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- the present invention provides compounds which are in a prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention.
- prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- the invention also provides a pharmaceutical composition, comprising an effective amount a compound described herein and a pharmaceutically acceptable carrier.
- compound is administered to the subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the compound to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
- Actual dosage levels and time course of administration of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic (or unacceptably toxic) to the patient.
- At least one compound according to the present invention is administered in a pharmaceutically effective amount to a subject in need thereof in a pharmaceutical carrier by intravenous, intramuscular, subcutaneous, or intracerebro ventricular injection or by oral administration or topical application.
- a compound of the invention may be administered alone or in conjunction with a second, different therapeutic.
- in conjunction with is meant together, substantially simultaneously or sequentially.
- a compound of the invention is administered acutely.
- the compound of the invention may therefore be administered for a short course of treatment, such as for about 1 day to about 1 week.
- the compound of the invention may be administered over a longer period of time to ameliorate chronic disorders, such as, for example, for about one week to several months depending upon the condition to be treated.
- pharmaceutically effective amount as used herein is meant an amount of a compound of the invention, high enough to significantly positively modify the condition to be treated but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
- a pharmaceutically effective amount of a compound of the invention will vary with the particular goal to be achieved, the age and physical condition of the patient being treated, the severity of the underlying disease, the duration of treatment, the nature of concurrent therapy and the specific organozinc compound employed. For example, a therapeutically effective amount of a compound of the invention administered to a child or a neonate will be reduced proportionately in accordance with sound medical judgment. The effective amount of a compound of the invention will thus be the minimum amount which will provide the desired effect.
- a decided practical advantage of the present invention is that the compound may be administered in a convenient manner such as by intravenous, intramuscular, subcutaneous, oral or intra-cerebroventricular injection routes or by topical application, such as in creams or gels.
- the active ingredients which comprise a compound of the invention may be required to be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
- the compound can be coated by, or administered with, a material to prevent inactivation.
- Dispersions can also be prepared, for example, in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the carrier can be a solvent or dispersion medium containing, for example, water, DMSO, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion.
- a coating such as lecithin
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the compound of the invention in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized compounds into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum-drying and the freeze-drying technique which yields a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
- the compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains compound concentration sufficient to treat a disorder in a subject.
- substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethycellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, manitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations such as Vitamin C, estrogen and echinacea, for example.
- Wetting agents and lubricants such as sodium lauryl
- Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application.
- the pharmaceutical composition should be formulated with a suitable ointment, lotion, or cream containing the active components suspended or dissolved in a carrier.
- Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, and water.
- the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier.
- Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.
- the pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches and iontophoretic administration are also included in this invention.
- the active compound(s), extracts, enriched extracts, or prodrug(s) can be formulated as solutions, gels, ointments, creams, suspensions, and the like.
- PRMT5:MEP50 protein complex was co-expressed in sf9 insect cells by Bac-to-Bac expression system and then purified by affinity chromatography and gel filtration. In silico molecular docking. Binding modes of designed small molecules are predicted by Autodock4. Surface Plasmon Resonance (SPR) binding analysis. Direct and competitive protein-ligand binding studies were performed on Biacore X100. Purified PRMT5:MEP50 was covalently attached to the CM5 sensor chip by amine coupling. Enzymatic inhibition assay. The enzymatic inhibition activity of designed compounds was determined by AlphaLISA assay and the mechanism of inhibition study was performed by MTase-Glo assay. Cancer cell lines.
- MCF-7 breast cancer cell line
- MDA-MB-231 triple negative breast cancer cell line
- MV4-11 ML-rearranged acute myeloid leukemia cell line
- Cell proliferation assay Anti-proliferative effects of designed molecules were tested in different cancer cell lines by MTT assay.
- Western blot Protein symmetric dimethylation level was assessed in MV4-11 cell line by pan-SDMA antibody and H4R3me2s antibody.
- Cell apoptosis analysis Apoptotic effect was evaluated by flow cytometry in MV4-11 cell line.
- Binding kinetics profiles are different between well-characterized cofactor analogs and our designed molecules.
- the fast-on fast-off binding mode suggests that they may not be strong binders. It is possible that the binding of designed molecules did not stabilize the critical loop at the active site which is flexible in the apo form of PRMT5.
- Inhibitor compounds are serial diluted by 5-fold to the desired concentrations in DMSO. Inhibitors are added into reaction buffer (30 mM Tris-HCl at pH 7.4, 500 mM NaCl, 2 mM MgCl2, 2 mM TCEP, 0.1% (wt/vol) BSA and 0.01% (vol/vol) Tween-20) with final DMSO concentration at 2% (vol/vol).
- the enzymatic inhibition assay is performed in a solid white low-volume 384-well plate (Greiner, #7784075) with total reaction volume of 16 ⁇ l and in the presence of 100 nM PRMT5:MEP50 enzymes, 10 ⁇ M SAM (Sigma-Aldrich, A4377), 2 ⁇ M substrate histone H4 (1-21) (ANASPEC, #AS-62499) and test compounds at indicated concentrations. Reactions without enzyme are conducted as negative control and reactions without compound are performed as positive control in every experiment. Methyltransferase reaction was started by adding 4 ⁇ l of SAM/H4 substrate mixture to each well that contains 8 ⁇ l enzyme and 4 ⁇ l test compound which are pre-mixed and incubated for 10 min.
- the reaction is performed at room temperature for 60 min followed by the addition of 4 ⁇ l 5 ⁇ MTase-Glo Reagent to produce SAH and concomitantly convert it to ADP. Mix the plate by shaking for 2 min, and incubate at room temperature for 30 min. Then, 20 ⁇ l room-temperature MTase-Glo Detection Solution is added and mixed well before incubating for another 30 min and recording luminescence. Luminescence is measured using the Synergy Neo2 HTS multimode microplate reader (BioTek). Each data point represents the average of three replicates; the error bars represent the standard deviation. Data are analyzed in GraphPad Prism 8. For inhibitor studies, IC 50 is determined by nonlinear regression (curve fit) using sigmoidal dose response (variable slope). RLU: Relative luminescence unit.
Abstract
Description
- This invention was made with government support under Grant No. CA212403 awarded by the National Institutes of Health. The government has certain rights in the invention.
- Protein arginine methyltransferase 5 (PRMT5), the major type II arginine methyltransferase, has been reported to have a series of bioactive functions during multiple cellular processes including tumorigenesis. Although the mechanism of PRMT5 related to tumorigenesis is still unclear, S-adenosylmethionine (SAM), as the co-factor of PRMT5, plays essential roles in the processes of methylating a variety of cytoplasmic and nuclear substrates that are involved in tumorigenesis. Typically, there are two types of
PRMT 5 inhibitors according to their binding sites. One targets the enzyme substrate site, whose binding is dependent of SAM or SAM analogues' binding, such as EPZ015666; the other targets co-factor site, such as LLY-283, which binds directly to SAM pocket and the majority of inhibitors in this type are nucleoside based. - Arginine methylation of proteins, as an important class of post-translational modification, plays a crucial function in a variety of cellular pathways including cell growth and proliferation, apoptosis, angiogenesis, and metastasis by regulating both transcriptional and post-transcriptional RNA processing.1 This modification is catalyzed by the protein arginine methyltransferase (PRMT), which transfers a methyl group from S-adenosylmethionine (SAM) to the terminal guanidino nitrogen atoms of arginine side-chains of histone and nonhistone proteins. So far nine human PRMTs have been reported and divided into type I, type II, and type III enzymes on the basis of specific kind of arginine methylation catalyzed. PRMT5 is the major type II PRMT which catalyzes the formation of ω-NG-monomethyl and ω-NG,N′G-symmetric dimethyl arginine residues. In the nucleus, PRMT5 has been shown to be involved in transcriptional repression including that of tumor suppressor and cell cycle genes like ST7 (suppressor of
tumorigenicity 7 protein),2 cyclin E1 and CDKN2A (cyclin-dependent kinase inhibitor 2A).3 These epigenetic modifications are catalyzed by PRMT5 through the symmetric dimethylation of histone H4 on the R3 residue (H4R3me2s) and on the R8 residue of histone H3 (H3R8me2s). H4R3me2s is generally associated with transcriptional repression,4 while H3R8me2s is seen as a mark for both transcriptional activation and repression.5 In the past decade, PRMT5 has attracted increasing attention as an anticancer target. It is overexpressed in various cancers, including lymphoma, prostate cancer, glioblastoma, and colorectal carcinoma and is associated with poor prognosis.6 Although Several small molecule inhibitors of PRMT5 have been reported,7-9 most of these are low potency inhibitors or lack cellular and/or in vivo activity. Typically, there are two types ofPRMT 5 inhibitors according to their binding sites. One targets the enzyme substrate site, whose binding is dependent of SAM or SAM analogues' binding, such as EPZ015666;10 the another targets co-factor site, such as LLY-283,11 which binds directly to SAM pocket and the majority of inhibitors in this type are nucleoside based. Here we describe a series of indole-based SAM competitive PRMT5 inhibitor compounds optimized from the lead compound (CMP5).12 The binding affinity and efficacy have been increased on the order of about 25-fold and 40-fold, respectively. Furthermore, the MTT assay shows that our compounds are effective in the MCF-7 cell line. - This invention is directed towards compounds, compositions, and methods of treating disease, disorders and conditions in a subject, including, inflammation, cancer, and autoimmune diseases by use of the compounds and compositions thereof.
- It is understood that the embodiments of the invention discussed below with respect to the preferred variable selections can be taken alone or in combination with one or more embodiments, or preferred variable selections, of the invention, as if each combination were explicitly listed herein.
- In one aspect, the invention is directed to a compound of Formula (I) or (II), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
- wherein each R1 is independently optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, or optionally substituted hydroxyalkyl;
each L is independently - and
each R2 is independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted —C(O)—NH-aryl, or optionally substituted —C(O)-heterocycloalkyl. - In one aspect, the invention is directed to a compound of Formula (I) or (II), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
- wherein each R1 is independently
- each L is independently
- each R2 is independently
- In another aspect, the compound of Formula (I) or (II), is any of
- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- In another aspect, the invention is directed to a compound of Formula (III), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
-
- wherein,
- Ar1 is a monocyclic or bicyclic aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ar1 is substituted with 0, 1, 2, 3, 4, or 5 Ry groups, as valency permits; each Ry is independently selected from the group consisting of halo, —CN, —NO2, optionally substituted aliphatic, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —ORA, —N(RB)2, —SRA, —C(═O)RA, —C(O)ORA, —C(O)SRA, —C(O)N(RB)2, —C(O)N(RB)N(RB)2, —OC(O)RA, —OC(O)N(RB)2, —NRBC(O)RA, —NRBC(O)N(RB)2, —NRBC(O)N(RB)N(RB)2, —NRC(O))RA, —S(O)RA, —C(═NRB)RA, —C(═NNRB)RA, —C(═NORA)RA, —C(═NRB)N(RB)2, —NRBC(═NRB)RB, —C(═S)RA, —C(═S)N(RB)2, —NRBC(═S)RA, —S(O)RA, —OS(O)2RA, —SO2RA, —NRBSO2RA, or —SO2N(RB)2;
- each RA is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
- each RB is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two RB groups are taken together with their intervening atoms to for an optionally substituted heterocyclic ring, which may be optionally substituted with 0, 1, 2, 3, 4, or 5 Rx groups;
- each RA and RB can be optionally substituted by one or more independent R5, R6, R7, and R8;
- each R5, R6, R7, and R8 is independently hydrogen, halo, or optionally substituted aliphatic;
- each Rx is independently selected from the group consisting of halo, —CN, optionally substituted aliphatic, —OR′, and —N(R″)2;
- each R′ is independently hydrogen or optionally substituted aliphatic;
- each R″ is independently hydrogen or optionally substituted aliphatic, or two R″ are taken together with their intervening atoms to form a heterocyclic ring: and n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, as valency permits;
- L is
- and
- Ar2 is any one of the following groups:
- In another aspect, the compounds of Formula III, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, are those wherein:
- Ar1 is any one of the following groups,
- In another aspect, the compounds of Formula III, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, is one of the following:
- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- In another aspect, the invention provides compounds, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, represented by Formula (IV) or (V):
- wherein
- each R1 is independently one of:
- Each L is independently:
- Each R2 is independently one of:
- In another aspect, the compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, is any of:
- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- In another aspect, the invention provides a pharmaceutical composition comprising the compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and a pharmaceutically acceptable carrier. In another aspect, the pharmaceutical composition further comprises an additional therapeutic agent (e.g., an anticancer agent).
- In other aspects, the invention provides a method of treating a disease, disorder, or symptom thereof in a subject, comprising administering to the subject any compound or composition delineated herein. In another aspect, the compound or composition is administered in an amount and under conditions sufficient to ameliorate the disease, disorder, or symptom thereof in a subject.
- In other aspects, the invention provides a method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- In other aspects, the invention provides a method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- In other aspects, the invention provides a method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said proliferative disease.
- In other aspects, the invention provides a method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said proliferative disease.
- In other aspects, the invention provides a method of modulating the proliferation activity in a subject, comprising contacting the subject with a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in an amount and under conditions sufficient to modulate proliferation activity.
- In one aspect, the invention provides a method of treating a subject suffering from or susceptible to a proliferation related disorder or disease, comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- In another aspect, the invention provides a method of treating a subject suffering from or susceptible to a proliferation related activity related disorder or disease, wherein the subject has been identified as in need of treatment for a proliferation related disorder or disease, comprising administering to said subject in need thereof, a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said disorder.
- In another aspect, the invention provides a method of treating a subject suffering from or susceptible to a cell proliferation related disorder or disease, wherein the subject has been identified as in need of treatment for a cell proliferation related disorder or disease, comprising administering to said subject in need thereof, a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that cell proliferation in said subject is modulated (e.g., down regulated). In another aspect, the compounds or compositions delineated herein preferentially target cancer cells over nontransformed cells.
- In another aspect, the proliferative disease is cancer.
- In another aspect, the cancer is multiple myeloma, lymphoma, chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), large granular lymphocyte leukemia (LGL), sarcoma, lung cancer, breast cancer, renal cancer, prostate cancer, pancreatic cancer, melanoma, colon carcinoma, gastric carcinoma, cervical cancer, ovarian cancer, liver cancer, or head and neck cancer.
- In a specific aspect, the invention provides a method of treating cancer, tumor growth, cancer of the colon, breast, bone, brain and others (e.g., osteosarcoma, neuroblastoma, colon adenocarcinoma), comprising administering to said subject in need thereof, an effective amount of any compound delineated herein, or a pharmaceutically acceptable salt thereof. Other cancers that may be treated by the compositions and methods of the invention include cardiac cancer (e.g., sarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma); lung cancer (e.g., bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma); various gastrointestinal cancer (e.g., cancers of esophagus, stomach, pancreas, small bowel, and large bowel); genitourinary tract cancer (e.g., kidney, bladder and urethra, prostate, testis; liver cancer (e.g., hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma); bone cancer (e.g., osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, cutaneous T-cell lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors); cancers of the nervous system (e.g., of the skull, meninges, brain, and spinal cord); gynecological cancers (e.g., uterus, cervix, ovaries, vulva, vagina); hematologic cancer (e.g., cancers relating to blood, Hodgkin's disease, non-Hodgkin's lymphoma); skin cancer (e.g., malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis); and cancers of the adrenal glands (e.g., neuroblastoma).
- In certain aspects, the disorder of uncontrolled cellular proliferation is cancer. In a further aspect, the cancer is selected from prostate cancer, lung cancer, colon cancer, pancreatic cancer, head & neck cancer, skin cancer, brain cancer, breast cancer, testicular cancer, and ovarian cancer. In a further aspect, the cancer is selected from melanoma, glioma, lymphoma, and leukemia.
- Methods delineated herein include those wherein the subject is identified as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
- The present invention is further described below with reference to the following non-limiting examples and with reference to the following figures, in which:
-
FIG. 1 . depicts (A) Arginine methylation reaction catalyzed by three types of PRMTs. (B) Chemical structures of SAM and SAH.13 -
FIG. 2 . depicts schematic representation of the AlphaLISA detection of a methylated histone peptide. (B: biotin group; R: arginine residue; Me: methyl group)14. -
FIG. 3 . depicts AlphaLISA assay protocol.14FIG. 4 . depicts lead optimization of compounds of the invention based on enzymatic assay. -
FIG. 5 . depicts the proposed binding poses ofCMP 5 bound toPRMT 5. -
FIG. 6 . depicts the proposed binding poses of 1-ET-1F bound toPRMT 5. -
FIG. 7 . depicts the overall structure of PRMT5:MEP50 complex (PDB code 4GQB). -
FIG. 8 . depicts SPR binding results of CMP5 and 6-1F. -
FIG. 9 . depicts MCF-7 cell viability ofPRMT 5 inhibitors -
FIGS. 10A-10B . depict MCF-7 and MCF-10A cell viability of 4-ET-3F (FIG. 10A ) and 8-ET-4F (FIG. 10B ). -
FIG. 11 . depictsScheme 1—synthetic route of 1-ET-1F15. -
FIG. 12 . depicts types of arginine methylation. -
FIG. 13 . depicts the crystal structure of human PRMT5:MEP50 (PDB 4GQB). - Currently, there are two classes of PRMT5 inhibitors. The first class is cofactor-competitive inhibitors, which are always cofactor analogs contain a nucleoside moiety whose ribose and adenine sub-structures are strongly favored by the Rossmann fold motif which recognizes nucleoside-based cofactors specifically. The second class is H4 substrate-competitive inhibitors. There are highly potent and selective inhibitors with enzymatic IC50 at single digit nanomolar level; however, their function relay on the pre-binding of cofactor SAM.
-
FIG. 14 . (A-F) depicts binding interactions of compounds. Based on the crystal structure of PRMT5, we have explored the entire active site and identified a novel lead compound CMP5 through virtual screening. The predicted binding mode of CMP5 shows a novel binding mechanism by occupying both cofactor and substrate binding sites. While the enzymatic inhibition activity of CMP5 was weak, we have optimized the compound by incorporating the quinolinamine moiety from a cofactor-competitive inhibitor JNJ-64619178. Here, we report a series of hybrid CMP5 analogs with increased potency by ˜50-fold (1-BUT-1F enzymatic IC50=7.89 μM). -
FIG. 15 . depicts chemical structures of PRMT5 inhibitors. -
FIG. 16 . depicts SPR binding experiments for binding affinity (KD) determination and competitive binding analysis for compounds. -
FIG. 17 . depicts (A-B) Mechanism of inhibition (MOI) study of 1-ET-1F by enzymatic assay suggested that it might be a substrate-competitive inhibitor. (C-D) predicted binding modes of 1-ET-1F at the substrate binding pocket in the presence of MTA. -
FIG. 18 . depicts (A) Anti-proliferative effect of designed molecules in different cancel cell lines (48h). (B) Western blot result showed a decreased protein symmetric demethylation level in MV4-11 cell line (48h). -
FIG. 19 . depicts apoptotic effects of 1-ET-1F in a dose-dependent manner in MV4-11 cell line. -
FIG. 20 depicts enzymatic inhibition assay results for 11-series compounds. -
FIG. 21 depicts enzymatic inhibition assay results for 15-series compounds. -
FIG. 22 depicts representative compound 11-9F binding to PRMT5 results using SPR/Biacore. Upper panel shows the compound binding to apo PRMT5/MEP50 complex with Kd of 4.3 uM; lower panel shows the compound binding to PRMT5/MTA/MEP50 holo complex with Kd of 162 nM. Together with the table (FIG. 23 ), this demonstrates that test compounds bind to PRMT5/MEP50 complex with or without MTA/SAM/SAH binding to the cofactor site, uniquely targeting MTAP deletion subset of cancers. -
FIG. 23 depicts enzymatic inhibition assay results and binding affinity results for test compounds. -
FIG. 24 depicts representative compound 11-9F cellular target engagement results using a Cellular Thermal Shift Assay. Left panel demonstrates that compared to negative control compound 11-3F, 11-9F binds to PRMT5 in the MDA-MB-231 triple negative breast cancer cells, resulting in increased thermal stability; right panel quantifies the PRMT5 melting temperature increase of 1.5 degree Celsius due to 11-9F binding. -
FIG. 25 depicts effects of compound 11-9F in cells, MDA-MB-231 breast cancer cell line. - In order that the invention may be more readily understood, certain terms are first defined here for convenience.
- As used herein, the term “treating” a disorder encompasses ameliorating, mitigating and/or managing the disorder and/or conditions that may cause the disorder. The terms “treating” and “treatment” refer to a method of alleviating or abating a disease and/or its attendant symptoms. In accordance with the present invention “treating” includes blocking, inhibiting, attenuating, modulating, reversing the effects of and reducing the occurrence of e.g., the harmful effects of a disorder.
- As used herein, “inhibiting” encompasses preventing, reducing and halting progression.
- As used herein, “activating” encompasses permitting, increasing and enhancing progression.
- The term “modulate” refers to increases or decreases in the activity of a cell in response to exposure to a compound of the invention.
- The terms “isolated,” “purified,” or “biologically pure” refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. Particularly, in embodiments the compound is at least 85% pure, more preferably at least 90% pure, more preferably at least 95% pure, and most preferably at least 99% pure.
- The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.
- A “peptide” is a sequence of at least two amino acids. Peptides can consist of short as well as long amino acid sequences, including proteins.
- The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
- The term “protein” refers to series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.
- Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
- As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.
- Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3rd ed., 1994) and Cantor and Schimmel, Biophysical Chemistry Part I. The Conformation of Biological Macromolecules (1980). “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 50 to 350 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β-sheet and α-helices. “Tertiary structure” refers to the complete three dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three dimensional structure formed by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.
- The term “administration” or “administering” includes routes of introducing the compound(s) to a subject to perform their intended function. Examples of routes of administration which can be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), topical, oral, inhalation, rectal and transdermal.
- The term “effective amount” includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result. An effective amount of compound may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the elastase inhibitor compound are outweighed by the therapeutically beneficial effects.
- The phrases “systemic administration,” “administered systemically”, “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes.
- The term “therapeutically effective amount” refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.
- A therapeutically effective amount of compound (i.e., an effective dosage) may range from about 0.005 μg/kg to about 200 mg/kg, preferably about 0.01 mg/kg to about 200 mg/kg, more preferably about 0.015 mg/kg to about 30 mg/kg of body weight. In other embodiments, the therapeutically effect amount may range from about 1.0 pM to about 10 μM. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a compound can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with a compound in the range of between about 0.005 μg/kg to about 200 mg/kg of body weight, one time per day for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. In another example, a subject may be treated daily for several years in the setting of a chronic condition or illness. It will also be appreciated that the effective dosage of a compound used for treatment may increase or decrease over the course of a particular treatment.
- The term “chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
- The term “diastereomers” refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.
- The term “enantiomers” refers to two stereoisomers of a compound which are non-superimposable mirror images of one another. An equimolar mixture of two enantiomers is called a “racemic mixture” or a “racemate.”
- The term “isomers” or “stereoisomers” refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
- The term “prodrug” includes compounds with moieties which can be metabolized in vivo. Generally, the prodrugs are metabolized in vivo by esterases or by other mechanisms to active drugs. Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Preferred prodrug moieties are propionoic acid esters and acyl esters. Prodrugs which are converted to active forms through other mechanisms in vivo are also included. In aspects, the compounds of the invention are prodrugs of any of the formulae herein.
- The term “subject” refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In certain embodiments, the subject is a human.
- The terms “a,” “an,” and “the” refer to “one or more” when used in this application, including the claims. Thus, for example, reference to “a sample” includes a plurality of samples, unless the context clearly is to the contrary (e.g., a plurality of samples), and so forth.
- Throughout this specification and the claims, the words “comprise,” “comprises,” and “comprising” are used in a non-exclusive sense, except where the context requires otherwise.
- As used herein, the term “about,” when referring to a value is meant to encompass variations of, in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.
- Furthermore the compounds of the invention include olefins having either geometry: “Z” refers to what is referred to as a “cis” (same side) conformation whereas “E” refers to what is referred to as a “trans” (opposite side) conformation. With respect to the nomenclature of a chiral center, the terms “d” and “1” configuration are as defined by the IUPAC Recommendations. As to the use of the terms, diastereomer, racemate, epimer and enantiomer, these will be used in their normal context to describe the stereochemistry of preparations.
- As used herein, the term “alkyl” refers to a straight-chained or branched hydrocarbon group containing 1 to 12 carbon atoms. The term “lower alkyl” refers to a C1-C6 alkyl chain. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, tert-butyl, and n-pentyl. Alkyl groups may be optionally substituted with one or more substituents.
- The term “haloalkyl” refers to an alkyl group that is substituted by one or more halo substituents. Examples of haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, bromomethyl, chloromethyl, and 2,2,2-trifluoroethyl.
- The term “alkenyl” refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon double bond. Alkenyl groups may be optionally substituted with one or more substituents.
- The term “alkynyl” refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing the 2 to 12 carbon atoms and at least one carbon-carbon triple bond. Alkynyl groups may be optionally substituted with one or more substituents.
- The term “arylalkynyl” refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon triple bond wherein one or more of the sp hybridized carbons of the alkynyl unit attaches to an aryl moiety. Alkynyl groups may be optionally substituted with one or more substituents.
- The sp2 or sp carbons of an alkenyl group and an alkynyl group, respectively, may optionally be the point of attachment of the alkenyl or alkynyl groups.
- The term “alkoxy” refers to an —O-alkyl radical.
- As used herein, the term “halogen”, “hal” or “halo” means —F, —Cl, —Br or —I.
- The term “alkylthio” refers to an —S-alkyl substituent.
- The term “alkoxyalkyl” refers to an -alkyl-O-alkyl substituent.
- The term “haloalkoxy” refers to an —O-alkyl that is substituted by one or more halo substituents. Examples of haloalkoxy groups include trifluoromethoxy, and 2,2,2-trifluoroethoxy.
- The term “haloalkoxyalkyl” refers to an -alkyl-O-alkyl′ where the alkyl′ is substituted by one or more halo substituents.
- The term “haloalkylaminocarbonyl” refers to a —C(O)-amino-alkyl where the alkyl is substituted by one or more halo substituents.
- The term “haloalkylthio” refers to an —S-alkyl that is substituted by one or more halo substituents. Examples of haloalkylthio groups include trifluoromethylthio, and 2,2,2-trifluoroethylthio.
- The term “haloalkylcarbonyl” refers to an —C(O)-alkyl that is substituted by one or more halo substituents. An example of a haloalkylcarbonyl group includes trifluoroacetyl.
- The term “cycloalkyl” refers to a hydrocarbon 3-8 membered monocyclic or 7-14 membered bicyclic ring system having at least one saturated ring or having at least one non-aromatic ring, wherein the non-aromatic ring may have some degree of unsaturation.
- Cycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a cycloalkyl group may be substituted by a substituent. Representative examples of cycloalkyl group include cyclopropyl, cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
- The term “cycloalkoxy” refers to an —O-cycloalkyl substituent.
- The term “cycloalkoxyalkyl” refers to an -alkyl-O-cycloalkyl substituent.
- The term “cycloalkylalkoxy” refers to an —O-alkyl-cycloalkyl substituent.
- The term “cycloalkylaminocarbonyl” refers to an —C(O)—NH-cycloalkyl substituent.
- The term “aryl” refers to a hydrocarbon monocyclic, bicyclic or tricyclic aromatic ring system. Aryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, 4, 5 or 6 atoms of each ring of an aryl group may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like.
- The term “aryloxy” refers to an —O-aryl substituent.
- The term “arylalkoxy” refers to an —O-alkyl-aryl substituent.
- The term “arylalkylthio” refers to an —S-alkyl-aryl substituent.
- The term “arylthioalkyl” refers to an -alkyl-S-aryl substituent.
- The term “arylalkylaminocarbonyl” refers to a —C(O)-amino-alkyl-aryl substituent.
- The term “arylalkylsulfonyl” refers to an —S(O)2-alkyl-aryl substituent.
- The term “arylalkylsulfinyl” refers to an —S(O)-alkyl-aryl substituent.
- The term “aryloxyalkyl” refers to an -alkyl-O-aryl substituent.
- The term “alkylaryl” refers to an -aryl-alkyl substituent.
- The term “arylalkyl” refers to an -alkyl-aryl substituent.
- The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-4 ring heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and the remainder ring atoms being carbon (with appropriate hydrogen atoms unless otherwise indicated). Heteroaryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may be substituted by a substituent. Examples of heteroaryl groups include pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoquinolinyl, indazolyl, and the like.
- The term “heteroaryloxy” refers to an —O-heteroaryl substituent.
- The term “heteroarylalkoxy” refers to an —O-alkyl-heteroaryl substituent.
- The term “heteroaryloxyalkyl” refers to an -alkyl-O-heteroaryl substituent.
- The term “nitrogen-containing heteroaryl” refers to a heteroaryl group having 1-4 ring nitrogen heteroatoms if monocyclic, 1-6 ring nitrogen heteroatoms if bicyclic, or 1-9 ring nitrogen heteroatoms if tricyclic.
- The term “heterocycloalkyl” refers to a nonaromatic 3-8 membered monocyclic, 7-12 membered bicyclic, or 10-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, S, B, P or Si, wherein the nonaromatic ring system is completely saturated. Heterocycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heterocycloalkyl group may be substituted by a substituent. Representative heterocycloalkyl groups include piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,3-dioxolane, tetrahydrofuranyl, tetrahydrothienyl, thiirenyl, and the like.
- The term “alkylamino” refers to an amino substituent which is further substituted with one or two alkyl groups. The term “aminoalkyl” refers to an alkyl substituent which is further substituted with one or more amino groups. The term “hydroxyalkyl” or “hydroxylalkyl” refers to an alkyl substituent which is further substituted with one or more hydroxyl groups. The alkyl or aryl portion of alkylamino, aminoalkyl, mercaptoalkyl, hydroxyalkyl, mercaptoalkoxy, sulfonylalkyl, sulfonylaryl, alkylcarbonyl, and alkylcarbonylalkyl may be optionally substituted with one or more substituents.
- Acids and bases useful in the methods herein are known in the art. Acid catalysts are any acidic chemical, which can be inorganic (e.g., hydrochloric, sulfuric, nitric acids, aluminum trichloride) or organic (e.g., camphorsulfonic acid, p-toluenesulfonic acid, acetic acid, ytterbium triflate) in nature. Acids are useful in either catalytic or stoichiometric amounts to facilitate chemical reactions. Bases are any basic chemical, which can be inorganic (e.g., sodium bicarbonate, potassium hydroxide) or organic (e.g., triethylamine, pyridine) in nature. Bases are useful in either catalytic or stoichiometric amounts to facilitate chemical reactions.
- Alkylating agents are any reagent that is capable of effecting the alkylation of the functional group at issue (e.g., oxygen atom of an alcohol, nitrogen atom of an amino group). Alkylating agents are known in the art, including in the references cited herein, and include alkyl halides (e.g., methyl iodide, benzyl bromide or chloride), alkyl sulfates (e.g., methyl sulfate), or other alkyl group-leaving group combinations known in the art. Leaving groups are any stable species that can detach from a molecule during a reaction (e.g., elimination reaction, substitution reaction) and are known in the art, including in the references cited herein, and include halides (e.g., I—, Cl—, Br—, F—), hydroxy, alkoxy (e.g., —OMe, —O-t-Bu), acyloxy anions (e.g., —OAc, —OC(O)CF3), sulfonates (e.g., mesyl, tosyl), acetamides (e.g., —NHC(O)Me), carbamates (e.g., N(Me)C(O)Ot-Bu), phosphonates (e.g., —OP(O)(OEt)2), water or alcohols (protic conditions), and the like.
- In certain embodiments, substituents on any group (such as, for example, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, heterocycloalkyl) can be at any atom of that group, wherein any group that can be substituted (such as, for example, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, heterocycloalkyl) can be optionally substituted with one or more substituents (which may be the same or different), each replacing a hydrogen atom. Examples of suitable substituents include, but are not limited to alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, halogen, haloalkyl, cyano, nitro, alkoxy, aryloxy, hydroxyl, hydroxylalkyl, oxo (i.e., carbonyl), carboxyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, aryloxycarbonyl, heteroaryloxy, heteroaryloxycarbonyl, thio, mercapto, mercaptoalkyl, arylsulfonyl, amino, aminoalkyl, dialkylamino, alkylcarbonylamino, alkylaminocarbonyl, alkoxycarbonylamino, alkylamino, arylamino, diarylamino, alkylcarbonyl, or arylamino-substituted aryl; arylalkylamino, aralkylaminocarbonyl, amido, alkylaminosulfonyl, arylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, imino, carbamido, carbamyl, thioureido, thiocyanato, sulfoamido, sulfonylalkyl, sulfonylaryl, or mercaptoalkoxy.
- Compounds of the invention can be made by means known in the art of organic synthesis. Methods for optimizing reaction conditions, if necessary minimizing competing by-products, are known in the art. Reaction optimization and scale-up may advantageously utilize high-speed parallel synthesis equipment and computer-controlled microreactors (e.g. Design And Optimization in Organic Synthesis, 2nd Edition, Carlson R, Ed, 2005; Elsevier Science Ltd.; Jahnisch, K et al, Angew. Chem. Int. Ed. Engl. 2004 43: 406; and references therein). Additional reaction schemes and protocols may be determined by the skilled artesian by use of commercially available structure-searchable database software, for instance, SciFinder® (CAS division of the American Chemical Society) and CrossFire Beilstein® (Elsevier MDL), or by appropriate keyword searching using an internet search engine such as Google® or keyword databases such as the US Patent and Trademark Office text database.
- As can be appreciated by the skilled artisan, methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art, including in the schemes and examples herein. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. In addition, the solvents, temperatures, reaction durations, etc. delineated herein are for purposes of illustration only and one of ordinary skill in the art will recognize that variation of the reaction conditions can produce the desired compounds of the present invention.
- The compounds herein may also contain linkages (e.g., carbon-carbon bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring or double bond. Accordingly, all cis/trans and E/Z isomers are expressly included in the present invention. The compounds herein may also be represented in multiple tautomeric forms, in such instances, the invention expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented. All such isomeric forms of such compounds herein are expressly included in the present invention. All crystal forms and polymorphs of the compounds described herein are expressly included in the present invention. Also embodied are extracts and fractions comprising compounds of the invention. The term isomers is intended to include diastereoisomers, enantiomers, regioisomers, structural isomers, rotational isomers, tautomers, and the like. For compounds which contain one or more stereogenic centers, e.g., chiral compounds, the methods of the invention may be carried out with an enantiomerically enriched compound, a racemate, or a mixture of diastereomers.
- The present invention also contemplates solvates (e.g., hydrates) of a compound of herein, compositions thereof, and their use in the treatment of a disease, disorder, or symptom thereof herein. As used herein, “solvate” refers to the physical association of a compound of the invention with one or more solvent or water molecules, whether organic or inorganic. In certain instances, the solvate is capable of isolation, for example, when one or more solvate molecules are incorporated in the crystal lattice of the crystalline solid.
- Preferred enantiomerically enriched compounds have an enantiomeric excess of 50% or more, more preferably the compound has an enantiomeric excess of 60%, 70%, 80%, 90%, 95%, 98%, or 99% or more. In preferred embodiments, only one enantiomer or diastereomer of a chiral compound of the invention is administered to cells or a subject.
- This invention is directed towards compounds, compositions, and methods of treating diseases and disorders by use of the compounds and compositions delineated herein.
- In other aspects, the invention provides a method of treating a disease, disorder, or symptom thereof in a subject, comprising administering to the subject any compound or composition delineated herein. In another aspect, the compound or composition is administered in an amount and under conditions sufficient to ameliorate the disease, disorder, or symptom thereof in a subject.
- In another aspect, the disease, disorder, or symptom includes proliferative diseases and disorders, cancer, tumor growth, cancer of the colon, breast, bone, brain and others (e.g., osteosarcoma, neuroblastoma, colon adenocarcinoma), cardiac cancer (e.g., sarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma); lung cancer (e.g., bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma); various gastrointestinal cancer (e.g., cancers of esophagus, stomach, pancreas, small bowel, and large bowel); genitourinary tract cancer (e.g., kidney, bladder and urethra, prostate, testis; liver cancer (e.g., hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma); bone cancer (e.g., osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, cutaneous T-cell lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors); cancers of the nervous system (e.g., of the skull, meninges, brain, and spinal cord); gynecological cancers (e.g., uterus, cervix, ovaries, vulva, vagina); hematologic cancer (e.g., cancers relating to blood, Hodgkin's disease, non-Hodgkin's lymphoma); skin cancer (e.g., malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis); and cancers of the adrenal glands (e.g., neuroblastoma).
- In another aspect, the inhibition is in vitro. In another aspect, the inhibition is in vivo. In another aspect, the method further comprises administering the compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, to a subject.
- In other aspects, the invention provides a method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- In other aspects, the invention provides a method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- In other aspects, the invention provides a method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said proliferative disease.
- In other aspects, the invention provides a method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said proliferative disease.
- In other aspects, the invention provides a method of modulating the proliferation activity in a subject, comprising contacting the subject with a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in an amount and under conditions sufficient to modulate proliferation activity.
- In one aspect, the invention provides a method of treating a subject suffering from or susceptible to a proliferation related disorder or disease, comprising administering to the subject a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- In another aspect, the invention provides a method of treating a subject suffering from or susceptible to a proliferation related activity related disorder or disease, wherein the subject has been identified as in need of treatment for a proliferation related disorder or disease, comprising administering to said subject in need thereof, a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that said subject is treated for said disorder.
- In another aspect, the invention provides a method of treating a subject suffering from or susceptible to a cell proliferation related disorder or disease, wherein the subject has been identified as in need of treatment for a cell proliferation related disorder or disease, comprising administering to said subject in need thereof, a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, such that cell proliferation in said subject is modulated (e.g., down regulated). In another aspect, the compounds or compositions delineated herein preferentially target cancer cells over nontransformed cells.
- In another aspect, the proliferative disease is cancer.
- In another aspect, the cancer is multiple myeloma, lymphoma, chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), large granular lymphocyte leukemia (LGL), sarcoma, lung cancer, breast cancer, renal cancer, prostate cancer, pancreatic cancer, melanoma, colon carcinoma, gastric carcinoma, cervical cancer, ovarian cancer, liver cancer, or head and neck cancer.
- In a specific aspect, the invention provides a method of treating cancer, tumor growth, cancer of the colon, breast, bone, brain and others (e.g., osteosarcoma, neuroblastoma, colon adenocarcinoma), comprising administering to said subject in need thereof, an effective amount of any compound or seaweed extract delineated herein, and pharmaceutically acceptable salts thereof. Other cancers that may be treated by the compositions and methods of the invention include cardiac cancer (e.g., sarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma); lung cancer (e.g., bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma); various gastrointestinal cancer (e.g., cancers of esophagus, stomach, pancreas, small bowel, and large bowel); genitourinary tract cancer (e.g., kidney, bladder and urethra, prostate, testis; liver cancer (e.g., hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma); bone cancer (e.g., osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, cutaneous T-cell lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors); cancers of the nervous system (e.g., of the skull, meninges, brain, and spinal cord); gynecological cancers (e.g., uterus, cervix, ovaries, vulva, vagina); hematologic cancer (e.g., cancers relating to blood, Hodgkin's disease, non-Hodgkin's lymphoma); skin cancer (e.g., malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis); and cancers of the adrenal glands (e.g., neuroblastoma). Other diseases and disorders that can be treated include the treatment of inflammatory disorders, neurodegenerative diseases, protozoal and latent viral infections, and (fibro)proliferative disorders.
- Methods delineated herein include those wherein the subject is identified as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
- In one aspect, the invention provides a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- In another embodiment, the invention provides a pharmaceutical composition further comprising an additional therapeutic agent. In another embodiment, the invention provides a pharmaceutical composition further comprising an additional therapeutic agent. In a further embodiment, the additional therapeutic agent is an anti-cancer agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, an anti-proliferation agent. In a further embodiment, the additional therapeutic agent is an anti-cancer agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, or an anti-proliferation agent.
- In one aspect, the invention provides a kit comprising an effective amount of a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in unit dosage form, together with instructions for administering the compound to a subject suffering from or susceptible to a proliferative disease, cancer (including diseases herein), solid tumor, angiogenesis, etc.
- In one aspect, the invention provides a kit comprising an effective amount of a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, or a pharmaceutical composition comprising a compound of any of the formulae herein (e.g., formulae (I)-(II), formulae (I)-(V)), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, in unit dosage form, together with instructions for administering the compound to a subject suffering from or susceptible to a cell proliferation disease or disorder, including cancer, solid tumor, angiogenesis, etc.
- The term “pharmaceutically acceptable salts” or “pharmaceutically acceptable carrier” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present invention.
- The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- The invention also provides a pharmaceutical composition, comprising an effective amount a compound described herein and a pharmaceutically acceptable carrier. In an embodiment, compound is administered to the subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the compound to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
- Actual dosage levels and time course of administration of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic (or unacceptably toxic) to the patient.
- In use, at least one compound according to the present invention is administered in a pharmaceutically effective amount to a subject in need thereof in a pharmaceutical carrier by intravenous, intramuscular, subcutaneous, or intracerebro ventricular injection or by oral administration or topical application. In accordance with the present invention, a compound of the invention may be administered alone or in conjunction with a second, different therapeutic. By “in conjunction with” is meant together, substantially simultaneously or sequentially. In one embodiment, a compound of the invention is administered acutely. The compound of the invention may therefore be administered for a short course of treatment, such as for about 1 day to about 1 week. In another embodiment, the compound of the invention may be administered over a longer period of time to ameliorate chronic disorders, such as, for example, for about one week to several months depending upon the condition to be treated.
- By “pharmaceutically effective amount” as used herein is meant an amount of a compound of the invention, high enough to significantly positively modify the condition to be treated but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. A pharmaceutically effective amount of a compound of the invention will vary with the particular goal to be achieved, the age and physical condition of the patient being treated, the severity of the underlying disease, the duration of treatment, the nature of concurrent therapy and the specific organozinc compound employed. For example, a therapeutically effective amount of a compound of the invention administered to a child or a neonate will be reduced proportionately in accordance with sound medical judgment. The effective amount of a compound of the invention will thus be the minimum amount which will provide the desired effect.
- A decided practical advantage of the present invention is that the compound may be administered in a convenient manner such as by intravenous, intramuscular, subcutaneous, oral or intra-cerebroventricular injection routes or by topical application, such as in creams or gels. Depending on the route of administration, the active ingredients which comprise a compound of the invention may be required to be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound. In order to administer a compound of the invention by other than parenteral administration, the compound can be coated by, or administered with, a material to prevent inactivation.
- The compound may be administered parenterally or intraperitoneally. Dispersions can also be prepared, for example, in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils.
- The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage. The carrier can be a solvent or dispersion medium containing, for example, water, DMSO, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the compound of the invention in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized compounds into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and the freeze-drying technique which yields a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
- For oral therapeutic administration, the compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains compound concentration sufficient to treat a disorder in a subject.
- Some examples of substances which can serve as pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethycellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, manitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations such as Vitamin C, estrogen and echinacea, for example. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, lubricants, excipients, tableting agents, stabilizers, anti-oxidants and preservatives, can also be present.
- Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application. For topical application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment, lotion, or cream containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate,
polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches and iontophoretic administration are also included in this invention. - For topical administration, the active compound(s), extracts, enriched extracts, or prodrug(s) can be formulated as solutions, gels, ointments, creams, suspensions, and the like.
- The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
- The present invention will now be demonstrated using specific examples that are not to be construed as limiting.
- The solvents and reagents used in the present study were purchased from commercial suppliers and were used as received. Progress of the chemical reactions was monitored by thin-layer chromatography on silica gel 60-F254 aluminum plates and detected under UV light. Silica gel for flash silica gel column chromatography was purchased from Sigma-Aldrich Chemical Co. (Milwaukee, Wis.). Proton nuclear magnetic resonance spectra were obtained with Bruker Avance 300 (300 MHz) or 400 (400 MHz) NMR spectrometer (Billerica, Mass.). Agilent LC/MSD TOF system G3250AA was used for the mass spectra measurements.
- The synthesis of the compounds can be accomplished by procedures known to one of skill in the art, and are also illustrated in the schemes and figures herein, or compounds (including starting materials, reagents, intermediates, etc.) are commercially available.
-
-
- Protein expression and purification. The PRMT5:MEP50 protein complex was co-expressed in sf9 insect cells by Bac-to-Bac expression system and then purified by affinity chromatography and gel filtration.
In silico molecular docking. Binding modes of designed small molecules are predicted by Autodock4.
Surface Plasmon Resonance (SPR) binding analysis. Direct and competitive protein-ligand binding studies were performed on Biacore X100. Purified PRMT5:MEP50 was covalently attached to the CM5 sensor chip by amine coupling.
Enzymatic inhibition assay. The enzymatic inhibition activity of designed compounds was determined by AlphaLISA assay and the mechanism of inhibition study was performed by MTase-Glo assay.
Cancer cell lines. MCF-7 (breast cancer cell line), MDA-MB-231 (triple negative breast cancer cell line) and MV4-11 (MLL-rearranged acute myeloid leukemia cell line).
Cell proliferation assay. Anti-proliferative effects of designed molecules were tested in different cancer cell lines by MTT assay.
Western blot. Protein symmetric dimethylation level was assessed in MV4-11 cell line by pan-SDMA antibody and H4R3me2s antibody.
Cell apoptosis analysis. Apoptotic effect was evaluated by flow cytometry in MV4-11 cell line. - The results provided conflicting data about the binding mechanism of the designed molecules. SPR binding results suggest that the parental compounds bind to PRMT5 directly while MOI study reveals that the inhibition activity relies on cofactor binding, which is surprisingly consistent with the SPR results of 1-BUT-1F. Structural characterizations are necessary to confirm the actual binding mode of designed molecules.
- Binding kinetics profiles are different between well-characterized cofactor analogs and our designed molecules. The fast-on fast-off binding mode suggests that they may not be strong binders. It is possible that the binding of designed molecules did not stabilize the critical loop at the active site which is flexible in the apo form of PRMT5.
- Selectivity among other types of PRMTs as well as cell toxicity and off-target effects need to be studied for the designed molecules.
- While the current two classes of inhibitors have their own limitation, it is worthwhile to design small molecule exhibiting novel inhibition mechanism. Our results show that the designed molecule 1-BUT-1F bind to MTA-bound PRMT5 with a higher binding affinity (KD=2.65 μM) than EPZ015666 (KD=20.4 μM, reported by RBC), which makes it feasible to design MTA-dependent substrate-competitive inhibitors at the substrate binding site. This is extremely useful for MTAP-deleted cancers where MTA is overexpressed.
- Based on the docking mode in the
human PRMT 5 crystal structure, fragment-based and structure-based design has led to a series of 1,2,3,4-tetrahydrocarbazole derivatives. Different from the previously reported compounds which are substrate site competitor or nucleoside analogues, our compounds based on 1,2,3,4-tetrahydrocarbazole target the cofactor site ofPRMT 5. Compared to the previous reported compound CMP5, the binding affinity and efficacy of new compounds have been improved. Furthermore, the MTT assay shows that our compounds are effective in the MCF-7 cell line. - Inhibitor compounds are serial diluted by 5-fold to the desired concentrations in DMSO. Inhibitors are added into reaction buffer (30 mM Tris-HCl at pH 7.4, 500 mM NaCl, 2 mM MgCl2, 2 mM TCEP, 0.1% (wt/vol) BSA and 0.01% (vol/vol) Tween-20) with final DMSO concentration at 2% (vol/vol). The enzymatic inhibition assay is performed in a solid white low-volume 384-well plate (Greiner, #7784075) with total reaction volume of 16 μl and in the presence of 100 nM PRMT5:MEP50 enzymes, 10 μM SAM (Sigma-Aldrich, A4377), 2 μM substrate histone H4 (1-21) (ANASPEC, #AS-62499) and test compounds at indicated concentrations. Reactions without enzyme are conducted as negative control and reactions without compound are performed as positive control in every experiment. Methyltransferase reaction was started by adding 4 μl of SAM/H4 substrate mixture to each well that contains 8 μl enzyme and 4 μl test compound which are pre-mixed and incubated for 10 min. The reaction is performed at room temperature for 60 min followed by the addition of 4
μl 5× MTase-Glo Reagent to produce SAH and concomitantly convert it to ADP. Mix the plate by shaking for 2 min, and incubate at room temperature for 30 min. Then, 20 μl room-temperature MTase-Glo Detection Solution is added and mixed well before incubating for another 30 min and recording luminescence. Luminescence is measured using the Synergy Neo2 HTS multimode microplate reader (BioTek). Each data point represents the average of three replicates; the error bars represent the standard deviation. Data are analyzed inGraphPad Prism 8. For inhibitor studies, IC50 is determined by nonlinear regression (curve fit) using sigmoidal dose response (variable slope). RLU: Relative luminescence unit. -
MTase-Glo enzymatic inhibition Compounds 15-1F 15-2F IC50 218.5 nM 151.8 nM -
MTase-Glo enzymatic inhibition Compounds 11-1F 11-2F 11-9F IC50 1.342 μM 0.883 μM 0.183 μM - The following are embodiments of the invention:
-
- 1. A compound of Formula (III), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
- Formula III
- 1. A compound of Formula (III), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
-
-
- wherein,
- Ar1 is a monocyclic or bicyclic aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ar1 is substituted with 0, 1, 2, 3, 4, or 5 Ry groups, as valency permits; each Ry is independently selected from the group consisting of halo, —CN, —NO2, optionally substituted aliphatic, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —ORA, —N(RB)2, —SRA, —C(═O)RA, —C(O)ORA, —C(O)SRA, —C(O)N(RB)2, —C(O)N(RB)N(RB)2, —OC(O)RA, —OC(O)N(RB)2. —NRBC(O)RA, —NRBC(O)N(RB)2, —NR BC(O)N(RB)N(RB)2, —NRBC(O)ORA, —SC(O)RA, —C(═NRB)RA, —C(═NNRB)RA, —C(═NORA)RA, —C(═NRB)N(RB)2, —NRBC(═NR″)RB, —C(═S)R A, —C(═S)N(RB)2, —NRBC(═S)RA, —S(O)RA, —OS(O)2RA, —SO2RA, —NRBSO2RA, or —SO2N(RB)2;
- each RA is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
- each RB is independently selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two RB groups are taken together with their intervening atoms to form an optionally substituted heterocyclic ring, which may be optionally substituted with 0, 1, 2, 3, 4, or 5 Rx groups;
- each RA and RB can be optionally substituted by one or more independent R5, R6, R7, and R8;
- each R5, R6, R7, and R8 is independently hydrogen, halo, or optionally substituted aliphatic;
- each Rx is independently selected from the group consisting of halo, —CN, optionally substituted aliphatic, —OR′, and —N(R″)2;
- each R′ is independently hydrogen or optionally substituted aliphatic;
- each R″ is independently hydrogen or optionally substituted aliphatic, or two R″ are taken together with their intervening atoms to form a heterocyclic ring; and n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, as valency permits;
- L is
-
- and
-
-
- Ar2 is any one of the following groups:
-
-
- 2. The compounds of Formula III in
embodiment 1, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, are those wherein:- Ar1 is any one of the following groups,
- 2. The compounds of Formula III in
-
- 3. The compound of any of embodiments 1-2, wherein R1 is
- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
-
- 4. The compound of any of embodiments 1-3, wherein L is
- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
-
- 5. The compound of any of embodiments 1-4, wherein Ar2 is
-
-
- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- 6. The compound of any of embodiments 1-5, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, that is one of the following:
-
-
-
- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- 7. A compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, represented by Formula (IV) or (V):
-
-
-
- wherein
- each R1 is independently one of:
-
-
-
- Each L is independently:
-
-
-
- Each R2 is independently one of:
-
-
- 8. The compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, of
embodiment 7, wherein each R1 is independently one of
- 8. The compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, of
-
- 9. The compound or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, of any of embodiments 7-8, wherein L is
-
- 10. The compound or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, of any of embodiments 7-9, wherein R2 is
-
- 11. The compound, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, of any of embodiments 7-10 that is any one:
-
-
- or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.
- 12. A compound of Formula (I) or (II), or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
-
-
-
- wherein,
- each R1 is independently optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, or optionally substituted hydroxyalkyl;
- each L is independently
-
- and
-
-
- each R2 is independently optionally substituted aryl, optionally substituted heteroaryl, optionally substituted —C(O)—NH-aryl, or optionally substituted —C(O)— heterocycloalkyl.
- 13. A compound of Formula (I) or (II) of embodiment 12, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof:
-
-
-
- wherein each R1 is independently
-
-
-
- each L is independently
-
-
-
- each R2 is independently
-
-
- 14. The compound of embodiment 12 or 13, or pharmaceutically acceptable salt thereof, that is any one of:
-
- 15. A pharmaceutical composition comprising a compound of any one of embodiments 1-14, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier.
- 16. The pharmaceutical composition of embodiment 15, further comprising an additional therapeutic agent.
- 17. The pharmaceutical composition of embodiment 16, wherein the additional therapeutic agent is an anticancer agent.
- 18. A method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any one of embodiments 1-14, or a pharmaceutical salt thereof, or a pharmaceutical composition of any one of embodiments 15-17.
- 19. A method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any one of embodiments 1-14, or a pharmaceutical salt thereof, or a pharmaceutical composition of any one of embodiments 15-17.
- 20. A method of treating a subject suffering from or susceptible to a proliferative disease, the method comprising administering to the subject a compound of any one of embodiments 1-14, or a pharmaceutical salt thereof, or a pharmaceutical composition of any one of embodiments 15-17, such that said subject is treated for said proliferative disease.
- 21. A method of treating a proliferative disease in a subject identified as in need thereof, the method comprising administering to the subject a compound of any one of embodiments 1-14, or a pharmaceutical salt thereof, or a pharmaceutical composition of any one of embodiments 15-17, such that said subject is treated for said proliferative disease.
- 22. The method of any one of embodiments 18-21, wherein the proliferative disease is cancer.
- 23. The method of any one of embodiments 18-22, wherein the cancer is multiple myeloma, lymphoma, chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), large granular lymphocyte leukemia (LGL), sarcoma, lung cancer, breast cancer, renal cancer, prostate cancer, pancreatic cancer, melanoma, colon carcinoma, gastric carcinoma, cervical cancer, ovarian cancer, liver cancer, or head and neck cancer.
-
- (1) Blanc, R. S.; Richard, S. Arginine methylation: the coming of age. Mol.
Cell 2017, 65, 8-24. - (2) Pal, S.; Vishwanath, S. N.; Erdjument-Bromage, H.; Tempst, P.; Sif, S. Human SWI/SNF-associated PRMT5 methylates
histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell. Biol. 2004, 24, 9630-9645. - (3) Fabbrizio, E.; El Messaoudi, S.; Polanowska, J.; Paul, C.; Cook, J. R.; Lee, J. H.; Negre, V.; Rousset, M.; Pestka, S.; Le Cam, A.; Sardet, C. Negative regulation of transcription by the type II arginine methyltransferase PRMT5. EMBO Rep. 2002, 3, 641-645.
- (4) Karkhanis, V.; Hu, Y. J.; Baiocchi, R. A.; Imbalzano, A. N.; Sif, S. Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem. Sci. 2011, 36, 633-641.
- (5) Xu, X.; Hoang, S.; Mayo, M. W.; Bekiranov, S. Application of machine learning methods to histone methylation ChIP-Seq data reveals H4R3me2 globally represses gene expression.
BMC Bioinformatics 2010, 11, 396. - (6) Stopa, N.; Krebs, J. E.; Shechter, D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell. Mol. Life Sci. 2015, 72, 2041-2059.
- (7) Kaniskan, H. U.; Jin, J. Recent progress in developing selective inhibitors of protein methyltransferases. Curr. Opin. Chem. Biol. 2017, 39, 100-108.
- (8) Hu, H.; Qian, K.; Ho, M. C.; Zheng, Y. G. Small molecule inhibitors of protein arginine methyltransferases. Expert Opin. Invest. Drugs 2016, 25, 335-358.
- (9) Mao, R.; Shao, J.; Zhu, K.; Zhang, Y.; Ding, H.; Zhang, C.; Shi, Z.; Jiang, H.; Sun, D.; Duan, W.; Luo, C. Potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor developed by structure-based virtual screening and hit optimization. J. Med. Chem. 2017, 60, 6289-6304.
- (10) Chan-Penebre, E.; Kuplast, K. G.; Majer, C. R.; Boriack-Sjodin, P. A.; Wigle, T. J.; Johnston, L. D.; Rioux, N.; Munchhof, M. J.; Jin, L.; Jacques, S. L.; West, K. A.; Lingaraj, T.; Stickland, K.; Ribich, S. A.; Raimondi, A.; Scott, M. P.; Waters, N. J.; Pollock, R. M.; Smith, J. J.; Barbash, O.; Pappalardi, M.; Ho, T. F.; Nurse, K.; Oza, K. P.; Gallagher, K. T.; Kruger, R.; Moyer, M. P.; Copeland, R. A.; Chesworth, R.; Duncan, K. W. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat. Chem. Biol. 2015, 11, 432-437.
- (11) Bonday, Z. Q.; Cortez, G. S.; Grogan, M. J.; Antonysamy, S.; Weichert, K.; Bocchinfuso, W. P.; Li, F.; Kennedy, S.; Li, B.; Mader, M. M.; Arrowsmith, C. H. LLY-283, a potent and selective inhibitor of
arginine methyltransferase 5, PRMT5, with antitumor activity. ACS Med. Chem. Lett. 2018, 11, 612-617. - (12) Alinari, L.; Mahasenan, K. V.; Yan, F.; Karkhanis, V.; Chung, J.-H.; Smith, E. M.; Quinion, C.; Smith, P. L.; Kim, L.; Patton, J. T.; Lapalombella, R.; Yu, B.; Wu, Y.; Roy, S.; De Leo, A.; Pileri, S.; Agostinelli, C.; Bradner, J. E.; Chen-Kiang, S.; Elemento, O.; Motiwala, T.; Majumder, S.; Byrd, J. C.; Jacob, S.; Sif, S, Li, C.; Baiocchi, R. A. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood, 2015, 125, 2530-2543.
- (13) Wang, Y.; Hu, W.; Yuan, Y. Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery. J. Med. Chem. 2018, 61, 9429-9441.
- (14) Beaudet, L.; Rodriguez-Suarez, R.; Venne, M. H.; Caron, M.; Bédard, J.; Brechler, V.; Parent, S.; Bielefeld-Sévigny, M. AlphaLISA immunoassays: the no-wash alternative to ELISAs for research and drug discovery. Nat. Methods. 2008, 5, A10-A11.
- (15) Cinelli, M. A.; Li, H.; Chreifi, G.; Martisek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition. J. Med. Chem. 2014, 57, 1513-1530.
- (16) Pal, Sharmistha, et al. Molecular and cellular biology 24.21 (2004): 9630-9645.
- (17) Antonysamy, Stephen, et al. PNAS 109.44 (2012): 17960-17965.
- (18) Alinari, Lapo, et al. Blood 125.16 (2015): 2530-2543.
- (19) Chan-Penebre, Elayne, et al. Nature chemical biology 11.6 (2015): 432-437.
- (20) Mavrakis, Konstantinos J., et al. Science 351.6278 (2016): 1208-1213.
- (21) Bonday, Zahid Q., et al. ACS medicinal chemistry letters 9.7 (2018): 612-617
- The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein in their entireties by reference.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended with be encompassed by the following claims.
Claims (22)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/599,505 US20230212143A9 (en) | 2019-03-29 | 2020-03-27 | Prmt5 inhibitor compounds |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962826933P | 2019-03-29 | 2019-03-29 | |
PCT/US2020/025534 WO2020205660A1 (en) | 2019-03-29 | 2020-03-27 | Prmt5 inhibitor compounds |
US17/599,505 US20230212143A9 (en) | 2019-03-29 | 2020-03-27 | Prmt5 inhibitor compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220185792A1 US20220185792A1 (en) | 2022-06-16 |
US20230212143A9 true US20230212143A9 (en) | 2023-07-06 |
Family
ID=72666560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/599,505 Pending US20230212143A9 (en) | 2019-03-29 | 2020-03-27 | Prmt5 inhibitor compounds |
Country Status (2)
Country | Link |
---|---|
US (1) | US20230212143A9 (en) |
WO (1) | WO2020205660A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
EP4288435A1 (en) * | 2021-02-04 | 2023-12-13 | Amgen Inc. | Tricyclic-amido-bicyclic prmt5 inhibitors |
WO2024008113A1 (en) * | 2022-07-07 | 2024-01-11 | 深圳微芯生物科技股份有限公司 | Formamide-substituted heterotricyclic derivative, method for preparing same, and use thereof |
WO2024012308A1 (en) * | 2022-07-15 | 2024-01-18 | 上海和誉生物医药科技有限公司 | Prmt5 inhibitor, preparation method therefor, and pharmaceutical use thereof |
WO2024074611A1 (en) * | 2022-10-05 | 2024-04-11 | Ryvu Therapeutics S.A. | Prmt5 inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9044432B2 (en) * | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
RS57023B1 (en) * | 2011-05-18 | 2018-05-31 | Janssen Sciences Ireland Uc | Quinazoline derivatives for the treatment of viral infections and further diseases |
JP6678455B2 (en) * | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | PRMT5 inhibitors and uses thereof |
JP6510485B2 (en) * | 2013-03-15 | 2019-05-08 | オハイオ・ステイト・イノベーション・ファウンデーション | PRMT5 inhibitors and methods of their use |
-
2020
- 2020-03-27 WO PCT/US2020/025534 patent/WO2020205660A1/en active Application Filing
- 2020-03-27 US US17/599,505 patent/US20230212143A9/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220185792A1 (en) | 2022-06-16 |
WO2020205660A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230212143A9 (en) | Prmt5 inhibitor compounds | |
US10562900B2 (en) | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | |
CA2629814C (en) | Bisamide inhibitors of hedgehog signaling | |
US9125915B2 (en) | Antitumor agent | |
PT2017278T (en) | Dihydropyrazolopyrimidinone derivative | |
US20160046616A1 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
US10017478B2 (en) | Inhibitors of ACK1/TNK2 tyrosine kinase | |
US11192900B2 (en) | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | |
ZA200608712B (en) | Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1II-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IkB kinase inhibitor | |
US10596152B2 (en) | Selenium containing KGA/GDH dual inhibitors and the applications thereof | |
US10336734B2 (en) | Inhibitors of ACK1/TNK2 tyrosine kinase | |
WO2009051909A1 (en) | Compounds having activity in correcting mutant-cftr cellular processing and uses thereof | |
KR20200089291A (en) | ACSS2 inhibitors and methods of use thereof | |
EA022434B1 (en) | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
JP6343034B2 (en) | Naphthyridinedione derivatives | |
WO2018236971A1 (en) | Single molecule compounds providing multi-target inhibition of parp and other proteins and methods of use thereof | |
JP6927548B2 (en) | Certain protein kinase inhibitors | |
EP2299996A1 (en) | 5-lipoxygenase inhibitors | |
KR20090102639A (en) | Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and process for preparing the same | |
TW201730188A (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
WO2007139492A1 (en) | Hexahydropyrimidine, tetrahydro imidazole or octahydroazepan derivatives | |
WO2022036313A1 (en) | Pyrimidinyl sulfonamides as inhibitors of ack1/tnk1 tyrosine kinase | |
RU2720180C2 (en) | Compounds used in treating neoplastic diseases | |
EP3980413B1 (en) | Heterocyclic immunomodulators as pdl1 checkpoint inhibitor | |
US20240002378A1 (en) | Merged scaffold taf1 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, CHENGLONG;YANG, XIAOZHI;ZHOU, WEI;SIGNING DATES FROM 20210505 TO 20210509;REEL/FRAME:058486/0577 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF FLORIDA;REEL/FRAME:065989/0604 Effective date: 20211119 |